Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry

Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry

Franck F Rahaghi,1 Richard Monk,2 Viswanathan Ramakrishnan,3 Tatsiana Beiko,2 Charlie Strange2 1Department of Pulmonary and Critical Care, Cleveland Clinic Florida, Weston, FL, USA; 2Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Medical University of South Carolina, Charleston, S...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron: Rahaghi FF, Monk R, Ramakrishnan V, Beiko T, Strange C
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Dove Medical Press 2020-12-01
Cyfres:International Journal of COPD
Pynciau:
alpha-1 antitrypsin deficiency
copd
mortality
augmentation therapy
fev1
survival
Mynediad Ar-lein:https://www.dovepress.com/alpha-1-antitrypsin-augmentation-therapy-improves-survival-in-severely-peer-reviewed-article-COPD

Rhyngrwyd

https://www.dovepress.com/alpha-1-antitrypsin-augmentation-therapy-improves-survival-in-severely-peer-reviewed-article-COPD

Eitemau Tebyg